A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Ross, Erin [1 ]
Ram, Lydia [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242137
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [22] Outcome of Peptide Receptor Radionuclide Treatment with Lu-177 DOTATATE from Ankara University.
    Soydal, C.
    Peker, A.
    Ozkan, E.
    Kucuk, O. N.
    Kir, M. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [23] Methodological Effects in Kidney Dosimetry in Lu-177 Radionuclide Therapy
    Heikkonen, J.
    Maenpaa, H.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S265 - S265
  • [24] A One-Year Review of the Radiation Safety Procedures and Protocols for Peptide Receptor Radionuclide Therapy (PRRT) Using Lutetium Lu 177 Dotatate
    Snyder, W.
    Schantz, P.
    Harpool, K.
    Dick, J. S.
    Cavanaugh, S. X.
    Swanson, J. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E613 - E614
  • [25] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    Targeted Oncology, 2024, 19 : 41 - 49
  • [26] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [27] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [28] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
  • [29] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Lubberink, Mark
    Garske-Roman, Ulrike
    Sundin, Anders
    CANCERS, 2021, 13 (05) : 1 - 15
  • [30] Dosimetric estimations using commercial workstations for peptide receptor radionuclide therapy (PRRT) patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S810 - S810
12345